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Abstract 
Background: Oncolytic virotherapy is a novel approach for the treatment of glioblastoma multiforme (GBM) which 
is still a fatal disease. Pathologic features of GBM are characterized by the infiltration with microglia/macrophages and 
a strong interaction between immune- and glioma cells. The aim of this study was to determine the role of microglia 
and astrocytes for oncolytic vaccinia virus (VACV) therapy of GBM.
Methods: VACV LIVP 1.1.1 replication in C57BL/6 and Foxn1nu/nu mice with and without GL261 gliomas was analyzed. 
Furthermore, immunohistochemical analysis of microglia and astrocytes was investigated in non-, mock-, and LIVP 
1.1.1-infected orthotopic GL261 gliomas in C57BL/6 mice. In cell culture studies virus replication and virus-mediated 
cell death of GL261 glioma cells was examined, as well as in BV-2 microglia and IMA2.1 astrocytes with M1 or M2 
phenotypes. Co-culture experiments between BV-2 and GL261 cells and apoptosis/necrosis studies were performed. 
Organotypic slice cultures with implanted GL261 tumor spheres were used as additional cell culture system.
Results: We discovered that orthotopic GL261 gliomas upon intracranial virus delivery did not support replication 
of LIVP 1.1.1, similar to VACV-infected brains without gliomas. In addition, recruitment of Iba1+ microglia and GFAP+ 
astrocytes to orthotopically implanted GL261 glioma sites occurred already without virus injection. GL261 cells in 
culture showed high virus replication, while replication in BV-2 and IMA2.1 cells was barely detectable. The reduced 
viral replication in BV-2 cells might be due to rapid VACV-induced apoptotic cell death. In BV-2 and IMA 2.1 cells with 
M1 phenotype a further reduction of virus progeny and virus-mediated cell death was detected. Application of BV-2 
microglial cells with M1 phenotype onto organotypic slice cultures with implanted GL261 gliomas resulted in reduced 
infection of BV-2 cells, whereas GL261 cells were well infected.
Conclusion: Our results indicate that microglia and astrocytes, dependent on their activation state, may preferen-
tially clear viral particles by immediate uptake after delivery. By acting as VACV traps they further reduce efficient virus 
infection of the tumor cells. These findings demonstrate that glia cells need to be taken into account for successful 
GBM therapy development.
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Background
Glioblastoma multiforme (GBM) is one of the most 
malignant form of brain cancer and the most frequent 
type of gliomas in adults [1]. Difficulties associated with 
the treatment of GBM are mainly due to the infiltrative 
nature of these tumors into the brain tissues as well as the 
function and morphology of the blood–brain barrier pre-
venting most therapeutics to reach the tumor sites [1, 2]. 
The success rate of conventional therapy is low and the 
prognosis for GBM is very poor, with a median survival 
time of less than 15 months [3], therefore, more emphasis 
on the research and development regarding alternative 
therapeutical approaches is essential. In this respect, the 
use of oncolytic viruses is an innovative and encourag-
ing strategy in cancer therapy [4–6]. Especially, vaccinia 
virus (VACV) is a very promising candidate in the field 
of oncolytic virotherapy of tumors [7–10]. Although 
oncolytic viruses can kill tumor cells grown in vitro with 
high efficiency, they often exhibit reduced replication 
capacity in  vivo, which results in a low therapeutic effi-
ciency in clinical trials [11]. These findings suggest that 
physiological aspects of the tumor microenvironment 
and host defense mechanisms decrease the virus’ thera-
peutic potential. Continued preclinical research aimed 
to understand and overcome virus inhibitory physiologi-
cal aspects is necessary. Two cell types present in brain 
tissues are suspected to be involved in the clearance of 
viral particles in the early stages of antitumor virother-
apy. On the one hand microglial cells, the resident mac-
rophages of the brain, quickly respond to a whole range 
of pathologic stimuli, e.g. virus infection [12–14]. At the 
same time, they exert an important neuroprotective role, 
for example, via phagocytosis of cellular debris after tis-
sue injury, and they act as antigen-presenting cells in 
adaptive immune responses [15]. Like peripheral mac-
rophages, microglia can exhibit either an acute inflam-
matory phenotype, referred to as classically activated or 
M1 microglia or an anti-inflammatory phenotype, also 
called alternatively activated or M2 microglia [16, 17]. 
Malignant gliomas may consist of up to 30% microglia 
[12, 18–20]. Interestingly, the local environment seems 
to determine the phenotype exhibited by microglia/mac-
rophages. Gliomas are found to actively suppress anti-
tumor activity of microglia e.g. by secretion of a variety 
of cytokines [21], which does result in promotion of the 
M2 phenotype and suppression of the M1 phenotype 
[22]. Several reports have shown a correlation between 
presence of microglial cells with M2 phenotype in glio-
mas and increasing tumor growth and poor prognosis 
[21, 23, 24]. In contrast, cells with the M1 phenotype are 
expected to be predominantly present at injection sites 
and also during the initial phases of tumor growth [24–
26]. However, so far no detailed characterization of cells 
with M1 and M2 phenotypes has been conducted dur-
ing glioma development [21]. In addition to microglia, 
astrocytes are also recruited to the tumor sites playing 
a role in the repair and scarring process following trau-
matic injuries [27, 28]. Astrocytes are derived from a het-
erogeneous population of progenitor cells present in the 
neuroepithelium of the developing CNS [27]. They are a 
heterogeneous population of cells thought to be involved 
in almost all aspects of brain functions, e.g. in biochemi-
cal support of endothelial cells that form the blood–brain 
barrier, in providing of nutrients to nervous tissues, as 
well as in maintenance of extracellular ion balance and 
transmitters [29, 30].
So far, there is little knowledge about the susceptibil-
ity of glial cells to VACV infection in adult brains and its 
possible outcome in the context of malignant gliomas. 
In the present study we examined whether murine glial 
cells are susceptible to VACV infection in cell culture and 
whether VACV can be used as a safe and efficient thera-
peutic agent in syngeneic mouse models for GBM. We 
further analyzed whether variable polarization of micro-
glia and astrocytes have any impact on VACV infection. 
For studying oncolytic virotherapy in an aggressive tumor 
model such as murine GL261 glioma, we used the VACV 
LIVP 1.1.1, which is a less-attenuated strain in compari-
son to e.g. the extensively studied triple mutant oncolytic 
VACV GLV-1h68 [31–35]. LIVP 1.1.1 is a replication-
competent wild-type isolate of the LIVP strain that has 
not been genetically modified but has a naturally occur-
ring disruption at the thymidine kinase (TK) gene locus 
(Chen et  al. manuscript in preparation) resulting in 




African green monkey kidney fibroblasts (CV-1) and 
the human primary glioblastoma cell line U87-MG were 
obtained from the American Type Culture Collection 
(ATCC). IMA2.1 cells were obtained from S. Schildkne-
cht (University of Konstanz, Germany). These cells are 
immortalized murine cortical astrocytes that respond 
to certain stimuli similarly to primary astrocytes with 
upregulation of specific mRNA resulting in expression of 
proteins [37]. BV-2 cells were kindly provided by M. Karl-
stetter (University Hospital Cologne, Germany). This cell 
line was derived from raf/myc-immortalized murine neo-
natal microglia and is the most frequently used substitute 
for primary microglia [38–40]. The murine glioblastoma 
cell line GL261 was kindly provided by A. Pagenstecher 
(Department of Neuropathology, University Hospital 
of Marburg, Germany). The identity of GL261 cells was 
confirmed by DNA sequencing by the Leibniz Institute 
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DSMZ—German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany).
All cell lines were cultured in DMEM supplemented with 
antibiotic-solutions (100 U/ml penicillin G, 100 U/ml strep-
tomycin, PAA Laboratories, Pasching, Austria) and with 
10% fetal bovine serum (FBS; PAA Laboratories). Cultures 
were maintained and incubated at 37°C with 95% humidity 
and 5% CO2. Growth medium was changed every third day 
until confluence.
Generation of U87‑MG‑RFP and GL261‑RFP cells
The cDNA sequence of the red fluorescent protein 
(mRFP1) was inserted into the U87-MG and GL261 cell 
genome as described previously in detail for the cell line 
C33A [41]. After transfection of U87-MG or GL261 cells 
with mRFP-encoding lentiviruses followed by blastici-
din selection (10  mg/ml, PAA Laboratories) one RFP-
expressing clone was selected and stable RFP expression 
was confirmed in 98% of all cells by flow cytometry.
Virus strains
LIVP 1.1.1 is a plaque purified isolate from the wild-
type stock of LIVP strain (Lister strain, Institute of Viral 
Preparations, Moscow, Russia). The sequence analysis of 
LIVP 1.1.1 revealed the presence of different mutations 
in several viral genes including that of thymidine kinase 
(TK) [31, 32]. GLV-2b372 is a virus construct derived 
from the parental LIVP 1.1.1 virus strain, which carries 
the TurboFP635 expression cassette under the control 
of the vaccinia synthetic early/late promoter in the TK 
locus.
Viral replication
Cells were grown in 24-well plates and infected with 
LIVP 1.1.1 at a multiplicity of infection (MOI) of 0.1. 
After 1  h of incubation at 37°C, the infection medium 
(infmed) was removed and replaced by fresh growth 
medium. After 2, 24, 48, 72, and 96  h cell pellets and 
supernatants were harvested. Following three freeze–
thaw cycles, serial dilutions of the lysates were titrated 
by standard plaque assay on CV-1 cells. All samples were 
measured in duplicate.
For analysis of viral titers from tissues, brains were 
excised 1, 3 and 7  days after intracranial/intratumoral 
LIVP 1.1.1 injection, they were minced, and 1 ml of ice-
cold phosphate buffered saline (PBS) was added. Sam-
ples were homogenized using a FastPrep homogenizer 
(Thermo Scientific, Karlsruhe, Germany).
Cell viability assay
After 24  h in culture, cells were infected with LIVP 
1.1.1 (MOI 1.0) for 1 h at 37°C. Afterwards the infection 
medium was replaced by fresh growth medium with 
or without cytokine supplement. The amount of via-
ble cells after infection was determined by uptake of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich, Taufkirchen, Germany). 
24, 48, 72, or 96 h after virus infection the medium was 
replaced by 0.5  ml MTT solution at a concentration of 
2.5  mg/ml MTT dissolved in DMEM without phenol 
red and incubated for 2 h at 37°C in the presence of 5% 
CO2. After removal of the MTT solution, 400 µl 1 N HCl 
diluted in isopropyl alcohol (Sigma-Aldrich) were added. 
The optical density was then measured at a wavelength of 
570 nm. Uninfected cells were used as controls and were 
considered as 100% viable or were used to determine the 
cell density.
Polarization experiments
For polarization experiments both 5  ×  104 BV-2 and 
IMA2.1 cells were plated in DMEM +  2% FBS in wells 
of 24-well plates and allowed to adhere for 20–24  h. 
24 h prior to infection, cells were stimulated either with 
1  µg/ml lipopolysaccharide (LPS, 026:B6 from E.coli, 
Sigma-Aldrich), LPS and rm-interferon-gamma (IFN-γ; 
10  ng/ml, Immunotools GmbH, Oldenburg, Germany), 
rm-IFN-γ alone, rm-interleukin-4 (IL-4; 10  ng/ml, 
Immunotools GmbH), or basic fibroblast growth factor 
(bFGF, 100  ng/ml, Millipore, Schwalbach, Germany) in 
DMEM +  2% FBS. Cells were infected with LIVP 1.1.1 
(MOI 1) for 1  h at 37°C. Infection medium was then 
replaced with fresh culture medium or culture medium 
supplemented with cytokines.
Griess assay
Nitrite (surrogate marker for nitric oxide [NO]) was 
measured by using the Griess reagent system (Promega, 
Mannheim, Germany) according to the manufacturer’s 
instructions.
Flow cytometry
For polarization experiments, BV-2 and IMA2.1 cells 
were incubated with rm-IL-4 or rm-IFN-γ as described 
above. Subsequently cells were trypsinized with 300  μl 
trypsin/EDTA (PAA Laboratories) until all cells were 
detached. The reaction was stopped by adding 600 μl of 
culture medium. Samples were centrifuged at 2,000 rpm 
for 3  min, 4°C and stained with the labeled monoclo-
nal antibody anti-mouse MHCII-PE (Clone M5, eBio-
science, Frankfurt, Germany) for 1  h at 4°C. Cells were 
washed once, resuspended in 200 µl PBS + 2% FBS, and 
analysis was done using the Accuri C6 Cytometer with 
FACS analysis software CFlow Version 1.0.227.4 (Accuri 
Cytometers, Inc., Ann Arbor, MI, USA).
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Apoptosis studies
Cells that have lost part of their DNA due to DNA frag-
mentation in late stage apoptosis are represented in 
sub-G1 peaks on DNA histograms [42]. For cell cycle 
analysis and detection of DNA fragmentation (sub-G1 
phase) GL261 and BV-2 cells were cultured in 24‐well 
plates for 24  h and infected with LIVP 1.1.1 (MOI 0.5), 
respectively. Cell pellets were resuspended in a solution 
of 100 µl PBS + 2% FBS and 5 µl propidium iodide (PI; 
1.0  µg/ml; Sigma-Aldrich). Prior to measurement, the 
suspension was frozen in liquid nitrogen and thawed at 
37°C.
To enable distinguishing apoptotic cells from necrotic 
cells a PI exclusion assay was performed. Based on the 
status of membrane damage the uptake kinetics of PI dif-
fer and cells can be distinguished into healthy (PI-nega-
tive), apoptotic (PI-dim), and necrotic (PI-bright) cells 
[43, 44]. For PI staining the cells were incubated with 1 µl 
PI for 5 min at room temperature and were subsequently 
analyzed as described above.
Western blot analysis
Cells were harvested and lysed in lysis buffer [50  mM 
Tris–HCl pH 7.4 (Carl Roth GmbH, Karlsruhe, Ger-
many), 150  mM NaCl (Sigma-Aldrich), 1  mM EDTA 
(Sigma-Aldrich), 1% Triton X-100 (Applichem, Darm-
stadt, Germany), 1% sodium desoxycholate (Carl Roth 
GmbH), 0.1% SDS (Carl Roth GmbH), 1 tablet Complete 
(Roche Diagnostics, Mannheim, Germany)]. The cell 
lysates were then separated on SDS-PAGE and proteins 
were transferred onto a nitrocellulose transfer mem-
brane (Whatman GmbH, Dassel, Germany). Polyclonal 
rabbit antibodies against iNOS (NB300-605, 1:500, 
Novus Biologicals, Ltd., Cambridge, UK) and arginase 
1 (H-52, 1:500, Santa Cruz Biotechnology Inc., Heidel-
berg, Germany) were used for incubation O/N at 4°C. 
The exposure time of the secondary antibody (horse-
radish peroxidase-conjugated anti-rabbit IgG; 1:5,000 
Santa Cruz Biotechnology Inc.) was 1 h at RT. Actin was 
detected using monoclonal anti-mouse actin antibody 
(ab6276, 1:10,000, abcam, Cambridge, UK) and a second-
ary horseradish peroxidase-conjugated antibody (anti-
mouse IgG, ab6728, 1:2,000, abcam). Peroxidase-bound 
protein bands were visualized using the enhanced chemi-
luminescence method.
Organotypic slice culture (OSC) preparation
OSCs were prepared as described by [45]. In brief, brains 
from 2 to 3 month old C57BL/6 mice were removed 
and immediately immersed in ice-cold Ringer solution 
[2.5  mM KCl (Merck KGaA, Darmstadt, Germany), 
1  mM MgCl2 (Sigma-Aldrich), 260  mM d-Glucose 
(Applichem), 26 mM NaHCO3 (Merck KGaA), 1.25 mM 
NaH2PO4 (Merck KGaA), 2 mM pyruvic acid (PAA Lab-
oratories), 3  mM myo-inositol (Sigma-Aldrich), 1  mM 
kynuric acid (Sigma-Aldrich), 2  mM CaCl2 (Carl Roth 
GmbH), pH 7.3]. The brains were embedded in 4% low 
melting agarose (Sigma-Aldrich). After polymerization 
agarose blocks were trimmed and glued onto the cutting 
table of a vibratome (VT1000, Leica, Heerbrugg, Switzer-
land). Brains were cut in coronal slices of 250 µm. Slices 
were then collected and stored in ice-cold Ringer solution 
before floating onto semi-porous membrane inserts (Mil-
lipore, 0.4 mm pore diameter) according to Stoppini et al. 
[46]. The slices were cultivated in wells of a 6-well plate at 
37°C under 5% CO2 in a standard medium consisting of 
DMEM/Ham’s F12 (pH 7.3; PAA Laboratories), 24% nor-
mal horse serum (PAA Laboratories), 2% HEPES (PAA 
Laboratories), 0.1% gentamycin (PAA Laboratories) and 
additional 10  mM d-glucose (Sigma-Aldrich). Medium 
was changed every other day and viability of brain slices 
was assessed using PI staining.
Implantation of tumor cells into OSCs
1 ×  104 U87-MG-RFP or GL261-RFP cells in a volume 
of 1 µl PBS were implanted with a Hamilton syringe into 
organotypic slice cultures 7  days after slice preparation. 
Starting 1  day after implantation, glioma growth and 
invasion were evaluated every other day using a MZ16 
FA Stereo-Fluorescence Microscope (Leica, Wetzlar, 
Germany).
Viral replication in OSCs
7 days after tumor cell implantation, the slices (5 slices/6-
well) were infected with 5 × 106 or 1 × 107 plaque form-
ing units (pfu) of virus diluted in 50 µl infection medium 
(DMEM/F12  +  2% FBS). Briefly, growth medium was 
replaced by 1  ml of infection medium and 10  µl virus 
solutions were pipetted onto each slice. The cultures were 
incubated for 3 h at 37°C. Then, 1 ml growth medium was 
added to the culture medium. Sections were harvested 
24 and 72 h after infection. Following three freeze–thaw 
cycles serial dilutions of the lysates were titrated by 
standard plaque assay on CV-1 cells. All samples were 
measured in triplicate.
Treatment and application of BV‑2 cells onto OSCs
To stimulate BV-2 microglia before application onto the 
OSCs, cells were treated with 10  ng/ml rm-IFN-γ or 
10 ng/ml rm-IL-4 (Immunotools GmbH) for 24 h. BV-2 
cells were then administered directly onto the implanted 
OSCs in a volume of 2 µl PBS containing 1 × 105 BV-2 
microglial cells. Unstimulated BV-2 cells were used as 
controls.
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Staining of OSCs
24 and 72  h after infection OSCs were fixed with 4% 
paraformaldehyde (AppliChem) in PBS, pH 7.4, for 16 h 
at 4°C followed by three repeated washing steps for 
15 min in PBS. The slice cultures were stored in PBS at 
4°C. Sections were blocked for 1 h with 5% FBS in PBS 
supplemented with 0.3% Triton X-100. Primary anti-
bodies against the glial fibrillary acidic protein (chicken 
anti-GFAP, ab4674, 1:100, abcam), specific for astrocytes, 
Iba-1 (rabbit anti-Iba-1, 1:100, Wako, Neuss, Germany) 
or FITC-coupled Griffonia simplicifolia Isolectin B4 (IB4) 
(1:50, Sigma-Aldrich), specific for microglia and anti-
VACV antibody (rabbit anti-Vaccinia, ab35219, 1:100, 
abcam) were applied into the blocking solution.
The slices were incubated for 3 days at 4°C with orbital 
shaking. Then the slices were washed three times with 
PBS (10  min each) and incubated with specific fluo-
rescence-labeled secondary antibodies (Cy2-donkey 
anti-rabbit 1:200, Cy5-donkey anti-chicken 1:200, both 
Dianova, Hamburg, Germany) in PBS for 4  h. The cell 
nuclei were stained subsequently with Hoechst 33342 
(Sigma-Aldrich). The procedure was finalized with three 
washing steps before the tissue slices were mounted on 
glass slides and embedded in mounting medium. All 
control experiments were performed without primary 
antibodies. Images were taken under the MZ16 FA Ste-
reo-Fluorescence microscope (Leica) equipped with a 
digital CCD camera (DC500, Leica) and at the Leica TCS 
SP2 AOBS confocal microscope equipped with an argon, 
helium neon and UV laser. Digital images (1,024 × 1,024 
pixel RGB-color images) were processed with Photoshop 
CS2 (Adobe Systems, Mountain View, CA) and merged 
to yield pseudo-colored images.
Intracranial tumor cell implantation and intratumoral/
intracranial virus injection
Animal studies were performed in accordance with pro-
tocols approved by the Institutional Animal Care and Use 
Committee (IACUC) of Explora Biolabs (San Diego, CA, 
USA, study number GL13-05B and GL13-17, protocol 
number EB11-025) or the government of Unterfranken 
(Wuerzburg, Germany, protocol number AZ 55.2-
2531.01-62/11). Four to five week old C57BL/6 or Foxn1 
nu/nu mice (Harlan) were anesthetized by intraperitoneal 
injection of a ketamine (Ketavet, Pharmacia GmbH, 
Berlin, Germany) and xylazine (Xylavet, CP-Pharma 
GmbH, Burgdorf, Germany) cocktail and immobilized in 
a stereotactic apparatus (Stoelting Instruments). GL261 
tumor cells (1x105 cells in 2  µl PBS) were implanted 
over a 5-min period, at coordinates 1.0 mm anterior and 
2.0 mm lateral to the bregma and 2.0 mm in depth using 
a Hamilton syringe. The incision was closed with surgical 
staples. Virus treatment was started 10 days after intrac-
ranial tumor cell implantation by a single intracranial/
intratumoral injection (5 ×  106  pfu in 2  µl PBS) over a 
5-min period of time. Mice without a tumor implantation 
just received the intracranial virus injection. Three mice 
per cohort were used in the study.
Immunohistochemical analyses of mouse brains
For histological studies, brains were excised and snap-
frozen in liquid nitrogen, followed by fixation in 4% para-
formaldehyde/PBS pH 7.4 O/N at 4°C. Fixed brains were 
rinsed with PBS and embedded in 5% (w/v) low-melting 
agarose, followed by preparation of sections  (100  µm) 
using a Leica VT1000S Vibratome. Tissue specimens 
were permeabilized and blocked in blocking solution for 
1  h. The tissue sections were then labeled with the pri-
mary antibodies anti-Iba-1, anti-GFAP and anti-VACV 
for 12–15 h. Sections stained with IB4-FITC were incu-
bated for an additional 24  h. After three washing steps 
in PBS, sections were incubated with secondary anti-
bodies [Dylight 488-, Cy3- and Alexa Fluor 647-conju-
gated (Dianova)] and Hoechst 33342 for 5 h. All sections 
were rinsed with PBS. In a final step, the sections were 
mounted onto glass slides in Mowiol 4–88 (Sigma-
Aldrich). The fluorescent-labeled preparations were 
examined as described above.
Measurement of the fluorescence intensity of Iba‑1 
and GFAP in GL261 brain tumor sections
Measurement of the fluorescence intensity of Iba-1 and 
GFAP stained slices was performed on 100  µm agarose 
sections  (three brain tumors per treatment conditions, 
in duplicate staining). Images were taken with identi-
cal camera settings. As described by Donat et  al. [47]. 
RGB-images were converted into 8-bit gray scale with 
an intensity range from 0 to 255 with Photoshop CS5 
(Adobe Systems, USA). The fluorescence intensity of 
Iba-1 and GFAP within the GL261 tumors represents 
the average brightness of staining related pixels and was 
measured with ImageJ. The tumor areas were determined 
with ImageJ. The fluorescence intensity was calculated as 
a ratio to the tumor area.
Statistical analysis
To determine significance between two conditions or 
treatment groups, a 2-tailed t test with unequal vari-
ances was used (Excel 2010 for Windows). P-values were 
defined as follows *p < 0.05, **p < 0.01, ***p < 0.001. For 
calculating boxplot diagrams a template from Vertex42 
LLC has been used.
Page 6 of 18Kober et al. J Transl Med  (2015) 13:216 
Results
Replication of intratumorally injected VACV LIVP 1.1.1  
was inhibited in orthotopic GL261 gliomas in mice
To analyze VACV progeny in orthotopic GL261 glio-
mas in vivo, two different mouse strains, immunocom-
petent C57BL/6 wild-type mice and immunodeficient 
athymic Foxn1nu/nu mice,  were injected intratumorally 
with 5 × 106 pfu/brain LIVP 1.1.1. Mice of both strains 
without GL261 gliomas (w/o) were used as controls 
(Figure 1a). We found that the virus titers were reduced 
in C57BL/6 wild-type mice with and without GL261 
tumors, from initially injected 5  ×  106 pfu/brain to 
1 ×  106 pfu/g brain tissues 1  day post infection (dpi). 
The titer further decreased to 5 × 104 and 1 × 104 pfu/g 
brain tissues at 7  dpi, respectively. Strikingly, similar 
results were obtained in immunodeficient Foxn1nu/
nu mice. Only very few LIVP 1.1.1 viral particles were 
detectable by immunohistochemistry within tumors at 
1 dpi (Figure 1b). This data implicates that VACV LIVP 
1.1.1 did not replicate efficiently in orthotopic GL261 
gliomas nor did it in healthy brains of immunocompe-
tent and immunodeficient mice. Only a very minor part 
of the viral inoculum remained viable within the brain 
for the 7 day time period.
Figure 1 Injection of VACV into mouse brain tissues with and without implanted gliomas. a C57BL/6 and Foxn1nu/nu mice with (w) and without 
(w/o) GL261 brain tumors were infected with 5 × 106 pfu LIVP 1.1.1 (i.t). For analysis of viral titers, brains were excised 1, 3 and 7 days after virus 
injection and analyzed by standard plaque assay [n = 4/5 per group (w) and n = 3 per group (w/o) tumor]. All samples were measured in duplicate 
(data are mean values ± SD; t test *p < 0.05). b Immunohistochemical staining for astrocytes (anti-GFAP, red) and VACV (anti-VACV, green) 1 dpi in 
GL261 implanted tumors. Shown are representative examples.
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Intratumoral injection of VACV into orthotopic GL261 
brain tumors did not alter the intratumoral amounts 
and distribution of microglia and astrocytes in C57BL/6 
mice
In a further step, the virus injection site in athymic Foxn1 
nu/nu mice without brain tumors was analyzed by immu-
nohistochemical stainings of brain sections 1 and 3 days 
post infection (dpi). For infection 5 × 106 pfu of the red 
fluorescent VACV strain GLV-2b372 was injected intrac-
ranially. A strong infiltration of immune cells to the injec-
tion site could be detected (Figure 2a, b): microglial cells 
stained with the microglial marker Iba-1 were already 
recruited 1  day after virus injection, whereas astrocytes 
stained with astrocytic marker GFAP were present after 
3 days. VACV replication detected by expression of Tur-
boFP635 was visible at the injection site (Figure 2a, b) but 
did not spread further through tissues.
Next, we set out to analyze the effects of VACV injec-
tion on these particular cell types under pathological 
conditions in wild-type mice with GL261 gliomas. The 
recruitment of both immune cell types was investigated 
in non-, mock-, and LIVP 1.1.1-infected tumors. Immu-
nohistochemical analysis of C57BL/6 mouse brains 1 day 
post intratumoral infection with LIVP 1.1.1 (Figure 2e, h) 
or PBS as control (Figure 2d, g) revealed a strong infiltra-
tion of the tumor with microglia (Iba-1+) and astrocytes 
(GFAP+) at both treatment conditions. GL261 cells were 
tested negative for GFAP (data not shown). Surprisingly, 
tumors without injection showed a similar infiltration 
pattern (Figure  2c, f ). Iba-1+ microglial cells were dis-
tributed homogenously throughout the tumor (center 
and rim), whereas GFAP+ astrocytes were located mainly 
at the periphery of the tumors (Figure  2c–e). However, 
quantitative analysis revealed no difference in the amount 
of Iba-1+cells and GFAP+ cells in untreated tumors com-
pared to mock or virus injected tumors 1 and 7 dpi (Fig-
ure 2i, j). Taken together, these findings indicate that the 
presence of microglia and astrocytes in GL261 gliomas is 
the consequence of the growing tumor [12, 18–20] and 
not caused by VACV infection.
In contrast to orthotopic GL261 gliomas, VACV replication 
was high in glioma tumor cells, very low in BV‑2 microglial 
cells, and absent in IMA2.1 astrocytes in cell culture
One explanation of reduced VACV replication in the 
mouse brain could be the preferential uptake of viral 
particles into microglia or astrocytes. We tested this 
hypothesis in cell culture, using two specific cell lines, 
BV-2 and IMA2.1, with similar growth characteristics as 
primary cells. To determine LIVP 1.1.1 virus progeny in 
these cell lines in vitro, cells were infected at an MOI of 
0.1 followed by standard plaque assay performed at dif-
ferent time points. Data was compared with infection of 
GL261 glioma cells under the same culture conditions 
(Figure  3a–c). We confirmed that LIVP 1.1.1 replicated 
efficiently in GL261 cells, determined by increasing 
cell-associated virus titers from 2 to 48 h post infection 
(hpi) and a plateau phase reached at 48 hpi at a virus 
dose of 1.5  ×  106  ±  2.1  ×  105 pfu/ml. Already, 24  hpi 
virus titers were higher than the infection medium 
(1.6 × 104 ± 2.3 × 103 pfu/ml). Virus titers in the super-
natant steadily increased over time, reaching a maximum 
at 96 hpi (2.9 × 105 ± 5.1 × 104 pfu/ml) (Figure 3a). In 
contrast, the virus titer in BV-2 cells remained slightly 
below the infection medium at all times that were ana-
lyzed except for the 48 hpi time point (Figure  3b). Sur-
prisingly, in IMA2.1 cells, the virus titer was far below 
the infection medium during the whole time course of 
the experiment (Figure 3c). No virus spreading occurred 
as indicated by the complete lack of viral particles in the 
supernatant of BV-2 and IMA2.1 infected cells. Cell via-
bility after virus infection was examined by MTT assay at 
an MOI of 1.0. The analysis showed that GL261 and BV-2 
cells were lysed upon infection with LIVP 1.1.1, whereas 
IMA2.1 cells were intact with a slight decrease in the 
amount of living cells (Figure 3d–f).
To analyze the competitive factors affecting virus rep-
lication we set up direct co-cultures of BV-2 and GL261 
cells in various concentrations for 24  h. For standard 
plaque assays cultures were infected at an MOI of 0.1 
in triplicates (Figure  3g–h). Virus replication was sig-
nificantly higher when GL261 cells were cultured alone 
than with BV-2 cells (50:50) 72 hpi. These effects can 
also be illustrated as ratio of the analyzed virus titers in 
culture and the infection medium (Figure 3h). In conclu-
sion, these experiments showed that the more BV-2 cells 
are present in the co-culture the less viral particles are 
detected over time. This finding may indicate that BV-2 
microglia may compete for virus uptake in culture.
Apoptosis and necrosis studies with BV‑2 and GL261 cells
VACV is known to induce either apoptosis or necrosis in 
different cell lines. Dependent on the infected cell type, 
apoptosis can be associated with reduced virus infec-
tion or replication [48]. Since replication analysis of LIVP 
1.1.1 in BV-2 and GL261 cells revealed a diverse efficacy 
of viral replication, but virus-mediated cell death was 
observed in both cell types, we investigated different 
mechanisms of cell death, i.e. apoptosis and necrosis, in 
these cell lines.
To quantify late apoptosis, the percentage of cells in 
sub-G1 phase was analyzed by flow cytometry. The per-
centages of mock-infected and VACV-infected cells in 
sub-G1 phase were compared at 24, 48, and 72 hpi (Fig-
ure 4a). We found that the percentage of cells in sub-G1 
phase was higher in BV-2 cells than in GL261 cells at all 
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Figure 2 Recruitment and infiltration of microglia and astrocytes into murine gliomas. a, b Recruitment of microglia and astrocytes 1 and 3 days 
after intracranial injection of GLV-2b372 into naïve Foxn1nu/nu mice stained with Hoechst (blue) to detect cell nuclei, IB4 (green) to stain microglia 
and GFAP to stain astrocytes (green). Virus was detected by expression of TurboFP635 (red). The VACV injection sites are marked by white arrows in 
the overlays. Immunohistochemical staining and analysis of GL261 gliomas in C57BL/6 mice untreated (w/o; c, f), injected intratumorally with PBS 
(d, g) or LIVP 1.1.1 (5 × 106 pfu) (e, h) at 1 dpi. Sections were stained for cell nuclei (blue), microglia (Iba-1+, red) and astrocytes (GFAP+, green). i, j 
Quantitative analysis of microglia and astrocytes 1 and 7 dpi (n = 3; analyzed in duplicate). Fluorescence intensity and tumor area were measured 
with ImageJ and calculated as ratio: Iba-1 or GFAP/tumor area. For box plot diagrams a template from Vertex42 LLC has been used.
Page 9 of 18Kober et al. J Transl Med  (2015) 13:216 
times. 40% of BV-2 cells were in sub-G1 phase after 24 
h and this amount of cells increased over time to 70% 
after 48 h and to 80% after 72 h. On the other hand, at 
24 hpi the amount of GL261 cells in sub-G1 phase was 
around 10% and increased to 45% after 72 h (Figure 4a). 
Additionally, distribution of PI-positive cells in PI-dim 
Figure 3 Analysis of VACV infections in murine GL261, microglial BV-2 and astrocytic IMA2.1 cells in cell culture. a–c Viral replication in GL261, BV-2 
and IMA2.1 cells infected with LIVP 1.1.1 at an MOI of 0.1 was analyzed by standard plaque assay. The red line separates active replication from no 
replication. d–f MTT assay was performed to detect the percentage of surviving cells after infection with LIVP 1.1.1 (MOI 1.0). g BV-2 and GL261 cells 
were cultured as direct co-cultures for 24 h in various concentrations. For standard plaque assay cells were infected at an MOI of 0.1 in triplicate. h 
Viral titers were related to the infection medium for a better comparison and illustrated as ratio (total virus titer/infection medium). Experiments 
were repeated in independent experiments. Two-sided t test with unequal variances was used for statistics (*p < 0.05).
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(apoptotic) and PI-bright (necrotic) cells [43, 44] revealed 
higher numbers of apoptotic cells in the VACV-infected 
BV-2 sample compared to infected GL261 cells at all time 
points (Figure 4b). Our data indicates that VACV infec-
tion activates different cell death pathways and mecha-
nisms in microglial BV-2 cells in contrast to GL261 
tumor cells.
LPS and IFN‑γ treatment in microglial BV‑2 cells further 
reduced virus progeny in vitro
Like peripheral macrophages also microglia take on 
either a classically activated M1 phenotype or an 
alternatively activated M2 phenotype [24]. We there-
fore set out to analyze both M1 and M2 phenotypes of 
BV-2 microglia for their ability to take up and support 
LIVP 1.1.1 virus replication. The two different pheno-
types M1 and M2 are dependent on exogenous addition 
of certain stimuli. Such stimuli are IL-4 for induction 
of the M2 phenotype, and IFN-γ or LPS or a combina-
tion of both for induction of the M1 phenotype [49]. 
LPS is known to induce nitric oxide (NO) production in 
BV-2 cells, a marker for the M1 phenotype [40, 50]. As 
shown in Figure  5a a low NO production indicated by 
the measurement of nitrite via Griess assay, was induced 
Figure 4 FACS analyses of GL261 and BV-2 cells. a Cells that have lost part of their DNA due to DNA fragmentation in apoptosis are represented in 
sub-G1 peaks on DNA histograms. The percentage of BV-2 or GL261 cells in sub-G1 phase 24, 48 or 72 h after viral infection (MOI 0.5) are shown in 
the bar chart. b The percentages of PI-dim (apoptotic) and PI-bright (necrotic) cells in controls and LIVP 1.1.1-infected samples (MOI 1.0) are shown 
for BV-2 and GL261 cells. The experiment was performed in triplicate and repeated in an independent experiment.
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Figure 5 Impaired amount of virus progeny after stimulation of BV-2 cells with IFN-γ or IFN-γ and LPS. BV-2 cells were stimulated with LPS (10 µg/
ml), IFN-γ, (10 ng/ml), LPS + IFN-γ or IL-4 (10 ng/ml) for 24 h in medium with 2% FBS. Polarization of cells was analyzed by Griess assay (a), Western 
blot (b) and by detection of the percentage of MHCII+ cells by FACS analysis (c). The amount of virus progeny (pfu/ml) was analyzed by standard 
plaque assay in the presence of stimulating factors and in normal growth medium in cells and supernatants (d). Statistical analysis was performed 
related to infection medium. To analyze the recovery of viral replication, normal growth medium was applied after infection of pre-stimulated cells. 
Standard plaque assay was performed to determine viral progeny in cells and supernatant after 24, 48, 72 and 96 hpi (e). To analyze the relative sur-
vival of the cells in the presence of stimulating factors a MTT assay was performed (f). The cellular density of stimulated cells relative to unstimulated 
(w/o) cells was detected via optical density measurement after 24 and 48 h of cultivation (g). Two-sided t test with unequal variances was used for 
statistics *p < 0.05, **p < 0.01, ***p < 0.001. Active replication was defined as virus titer above the virus titer of the infection medium (red line). All 
experiments were performed in triplicate and repeated in an independent experiment.
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by treating BV-2 cells with IFN-γ or LPS alone. However, 
when cells were treated with IFN-γ and LPS in combina-
tion, NO production was at the highest level, indirectly 
measured by the amount of nitrite (12.31  ±  1.61  µM). 
Western Blot analysis of total protein amounts extracted 
from treated BV-2 microglial cells indicated that the 
increase in NO production by IFN-γ and LPS resulted 
in an up-regulation of the inducible isoform of nitric 
oxide synthase (iNOS) (Figure  5b). In addition, treat-
ment of BV-2 cells with IL-4 or LPS both increased the 
expression of arginase 1, a marker for the M2 pheno-
type. Treatment of BV-2 cells with IFN-γ led to a reduc-
tion of arginase 1 expression. Furthermore, treatment 
of BV-2 cells with IFN-γ for 24 h resulted in high-level 
expression of MHCII molecules, an indicator for the M1 
phenotype, whereas MHCII expression was not detect-
able in unstimulated or IL-4 stimulated cells detected 
by FACS analysis (Figure  5c). Cells pre-incubated with 
LPS, IFN-γ, or LPS and IFN-γ and infected with LIVP 
1.1.1 revealed a reduced amount of viral progeny 24 and 
72 hpi (Figure  5d). In contrast, there was no difference 
between IL-4 or unstimulated cells. Interestingly, viral 
replication could be restored after medium change. We 
detected a continuous increase of the virus titer in cells 
pre-incubated with either LPS or LPS and IFN-γ when 
cells were cultured in normal growth medium after virus 
infection. The virus titer was higher than the infection 
medium at 72 and 96 hpi, respectively (Figure 5e). MTT 
assay revealed that around 50% of cells stimulated with 
IFN-γ or LPS and IFN-γ were alive 96 hpi, ~20% of sur-
viving cells were detected in the LPS treated samples 
and less than 10% of surviving cells were detected in the 
IL-4 and unstimulated samples (Figure 5f ). Furthermore, 
BV-2 cells which were stimulated with IFN-γ and/or LPS 
proliferated to a lesser extent than unstimulated or IL-4 
stimulated cells as indicated by the cellular density at 24 
and 48 h which was calculated relative to unstimulated 
cells. (Figure  5g). Based on virus replication and virus-
mediated cell death, these results strongly indicate pre-
ferred virus infection of cells of the M2 phenotype or 
unstimulated form of BV-2 cells in comparison to the 
M1 phenotype.
Application of LPS and IFN‑γ negatively affected viral 
particle production in IMA2.1 astrocytic cells
Polarization towards the M1 or M2 phenotypes is also 
known to occur in activated astrocytes [29]. The cell line 
IMA2.1 is known to respond similarly to stimuli like pri-
mary astrocytes [37]. We tested the ability of different 
pro-inflammatory cytokines (IL-4 and IFN-γ) and LPS 
to induce NO production in IMA2.1 cells. We also tested 
the effect of bFGF on IMA2.1 cells since bFGF like IL-4 
is known to enhance the proliferation of astrocytes [51]. 
We have found that there was no increase in NO levels 
after treatment with different stimulating factors shown 
as measurement of nitrite in Figure 6a. In addition, iNOS 
expression levels were not detectable via Western blot. 
Only arginase 1 was detectable after IL-4 treatment (Fig-
ure  6b). Surprisingly, FACS analyses revealed increased 
MHCII expression in IMA2.1 cell cultures after stimula-
tion with IFN-γ for 24 h as marker for the M1 phenotype 
(Figure 6c).
There was no effect on virus-mediated cell death 
under any of the treatment conditions (Figure  6d). 
Infection of cells treated with IFN-γ or LPS and IFN-γ 
resulted in a further reduction of viral particles com-
pared to unstimulated cells (Figure  6e). Furthermore, 
the amount of viral particles in cell cultures remained 
below the levels of the infection medium under all treat-
ment conditions.
LIVP 1.1.1 did not replicate efficiently in GL261 tumor 
spheres in organotypic slice cultures
We established organotypic slice cultures (OSCs) from 
2 to 3  month old C57BL/6 mice, the same age as the 
mice that received intracranial injections. The murine 
GL261 glioma cell line can be viewed as syngeneic non-
responder tumor model [52] and the human U87-MG 
glioblastoma cell line, in contrast, as the responder 
model [53]. OSCs were implanted with either GL261-
RFP or U87-MG-RFP cells and the tumors were 
allowed to establish for 7  days. The OSCs containing 
the tumors were infected with 5x106 pfu LIVP 1.1.1 
by adding VACV directly onto the tumor spheres (Fig-
ure  7a). Viral plaque assay of OSCs with GL261-RFP 
tumors revealed no difference of the virus titer between 
24 and 72 h. In contrast, U87-MG-RFP tumors showed 
a tenfold increase of VACV LIVP 1.1.1 progeny after 
72  h (Figure  7b). Immunohistochemical staining of 
tumor spheres (Figure 7c) confirmed that VACV is able 
to infect GL261 tumors expressing RFP but viral parti-
cles were only detectable at the periphery of the tumor. 
In contrast, OSCs with U87-MG tumors expressing 
RFP were completely infected 72 h after addition of 
the virus onto the slices (Figure  7d). The same results 
were observed in OSCs derived from an immunodefi-
cient mouse brain (data not shown). Here the results 
obtained from intracranial implantation and infec-
tion experiments were also confirmed in OSC tumors 
ex vivo.
Microglia could be protected from infection with VACV 
LIVP 1.1.1 in OSCs
With OSCs we further attempted to determine the role 
of phagocytic microglia in mouse brain tumors. We 
performed exogenous application of BV-2 microglia to 
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the OSCs which were treated with different cytokines 
in advance. GL261 cells were implanted into OSCs and 
allowed to establish for 7 days. In a second step micro-
glial BV-2 cells either non-stimulated or stimulated for 
24  h with IFN-γ or IL-4 were added onto OSCs. One 
day after addition of BV-2 microglial cells, OSCs were 
infected with VACV for 24 h. BV-2 microglial cells were 
stained with FITC-IB4. Representative images of immu-
nohistochemical stainings showed that unstimulated 
BV-2 cells located around the tumor cells were infected 
with LIVP 1.1.1, whereas the GL261 tumor cells were 
only partially infected (Figure 7e). Studies of BV-2 cells 
stimulated with IL-4 prior to application showed similar 
results (data not shown). Interestingly, BV-2 cells stimu-
lated with IFN-γ for 24 h prior to application were not 
infected, however GL261 tumor cells in contrast were 
well infected (Figure  7f ). From these promising pre-
liminary results we concluded that OSCs are a suitable 
method to model ex  vivo interactions of conditioned 
immune cells, intracellular pathogens and tumor cells 
for the understanding of possible interactions in the 
tumor microenvironment.
Discussion
In this study, we examined how glial cells and the tumor 
microenvironment affected the efficacy of oncolytic 
VACV LIVP 1.1.1 infection in intracranial GL261 tumor 
models and in cell culture systems. It is common knowl-
edge that glioma cells release factors for active attrac-
tion of immune cells at injury- and tumor sites [21, 54, 
55]. Here we found that non-infected GL261 tumors 
at an early stage are heavily infiltrated by microglia 
and astrocytes, most likely recruited by the tumor cell 
implantation. Interestingly, the amounts of microglia and 
astrocytes were not significantly different in PBS- and 
VACV-injected tumors at day 1 and 7. It was observed 
that amounts of microglia were increased in proportion 
with tumor growth. We concluded therefore that preex-
isting infiltration in tumors and not the VACV injection 
caused the extensive recruitment. Further results showed 
Figure 6 Stimulation of IMA 2.1 cells had no effect on relative survival after viral infection. IMA 2.1 cells were stimulated with LPS (10 µg/ml), IFN-γ, 
(10 ng/ml) LPS + IFN-γ, IL-4 (10 ng/ml), FGF (5 ng/ml) or FGF + LPS for 24 h in medium with 2% FBS. Polarization of cells was analyzed by Griess 
assay (a), Western blot (b) and FACS analysis by detection of MHCII+ cells (c). d MTT assay was performed to detect the relative percentage of VACV-
mediated cell death in the presence of stimulating factors. e Viral replication was analyzed by standard plaque assay in the presence of stimulating 
factors. All experiments were performed in triplicate.
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Figure 7 Analysis of VACV infection in organotypic slice cultures with tumor cell implants. a Organotypic slice cultures (OSCs) from adult mice were 
established and implanted with 1 × 104 Gl261-RFP or U87-MG-RFP cells. 7 days after implantation, OSCs were infected with 5 × 106 pfu LIVP 1.1.1/
well. b Standard plaque assay was performed 24 and 72 h after infection. Two-sided t test with unequal variances was used for statistics *p < 0.05. 
72 h after infection OSCs implanted with GL261-RFP (c) and U87-MG-RFP (d) cells were stained with Hoechst and anti-VACV antibody to visualize 
infected tumor spheres. e, f IFN-γ-stimulated or unstimulated BV-2 cells were applied directly onto the OSCs implanted with GL261 cells. 24 h later 
OSCs were infected with LIVP 1.1.1 and stained after additional 24 h with FITC-IB4, Hoechst and anti-VACV antibody. Yellow arrows indicate exempla-
rily infected or non-infected BV-2 microglial cells.
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that LIVP 1.1.1 was neither able to replicate efficiently in 
the orthotopic GL261 tumors nor in the healthy brains of 
immunocompetent as well as immunodeficient mice.
No significant differences between virus titers of 
immunodeficient and immunocompetent mice with 
orthotopic GL261 gliomas were detected. This finding 
may be explained by the fact that the brain in contrast 
to the periphery is defined as an “immune privileged” 
or “immune specialized” organ [56–59]. The differences 
between the immune system in the brain and the periph-
ery include but are not limited to a reduced number of 
antigen-presenting cells in the brain tissues, only few and 
activated lymphocytes that can enter the brain tissues, 
no traditional lymphatic system present in the brain, and 
finally engrafted tissues in the CNS are slower rejected 
than transplants somewhere else in the body [56–59].
In a separate study we showed, that the VACV titer 
in subcutaneous GL261 tumors in C57BL/6 mice was 
dependent on endogenous IFN-γ levels within the tumor 
microenvironment [52]. Due to the constitution of the 
intracranial GL261 tumors possible explanations for the 
reduced viral replication might be in addition the uptake 
of viral particles into microglia and into astrocytes. This 
hypothesis was further analyzed in cell culture studies. 
For this experiment, the well-established murine micro-
glial cell line BV-2 was used. We showed that BV-2 cells 
took up LIVP 1.1.1 but the amount of virus progeny 
was very low in comparison to GL261 glioma tumor 
cells. Infection of BV-2 microglial cells with LIVP 1.1.1 
resulted in cell lysis in cell culture and we confirmed 
that VACV LIVP 1.1.1 induced apoptosis in murine 
BV-2 cells. However, more of the tumor cells exhibited a 
necrotic state after infection. Liskova et  al. showed that 
VACV can induce either apoptosis or necrosis in differ-
ent cell types [48]. Humlová and colleagues reported that 
VACV infection in fact induces apoptosis in J774 murine 
macrophages [60]. We argued that after virus infection 
microglial cells become apoptotic, and therefore no fur-
ther viral spreading may occur.
We also found that the astrocytic cell line IMA2.1 was 
infected by LIVP 1.1.1 as determined by standard plaque 
assays. However, the replication was abortive. Further-
more, the lack of replication did not yield cell lysis. Taken 
together, as both BV-2 microglia and IMA2.1 astrocytes 
did not support active viral replication we concluded that 
both cell types may function as cell traps for VACV.
In gliomas the interplay with myeloid cells in the tumor 
microenvironment is a decisive factor [18]. Glioma cells 
secrete factors such as IL-10, IL-4, IL-6, M-CSF, TGF-β, 
and prostaglandin E2 that suppress the immune func-
tions of microglia when these cells are located inside 
the tumor [21, 54]. These cytokines are known to pro-
mote a shift to M2 phenotypes and at the same time to 
suppress the M1 phenotype. Gliomas also secrete fac-
tors which lead to polarization of the M1 phenotype in 
microglia/macrophages. There is an intense controversy 
about the amounts of M1 and M2 phenotypes inside the 
tumor mass [17, 21, 22]. For example, Glass and Synowitz 
observed that tumor-associated macrophages in gliomas 
have an aberrant immune type which shares both M1 
and M2 features [18]. In addition, findings concerning 
VACV infection of immune cells e.g. macrophages are 
controversially discussed in literature. To name only two 
examples: Broder et al. [61] mentioned that human pri-
mary macrophages do not support productive infection 
of VACV which is consistent with results from primary 
mouse and rabbit macrophages. In a study of Byrd et al. 
[62] it was demonstrated that primary human mono-
cyte derived macrophages (MDMs) with either M1- or 
M2-phenotype do support VACV replication in contrast 
to AB-serum-derived MDMs.
In the present study, the M1 and M2 phenotypes of 
BV-2 microglia and IMA2.1 astrocytes were analyzed 
after infection with VACV LIVP 1.1.1. Table  1 summa-
rizes the polarization experiments of both cell lines BV-2 
and IMA 2.1 based on VACV replication and VACV-
mediated cell death. The use of LPS or IFN-γ alone, LPS 
and IFN-γ in combination, all of which turn the cells into 
M1 phenotypes, resulted in a reduction of viral particles 
in BV-2 cells. LPS and IFN-γ together had cumulative 
effects. In unstimulated cells viral particles were detect-
able after 72 h but replication efficacy did not reach the 
initial infection medium. Treatment with IL-4 showed 
similar results when compared to unstimulated BV-2 
cells.
Table 1 Summary of  treatment conditions on  BV-2 
and IMA2.1 cells and their effects on VACV infection
nt not tested, w/o without stimulation.
a Virus progeny (24 and 72 hpi) related to the infection medium was determined 
by standard plaque assays. [+] indicates an increase of the virus titer from the 
infection medium, [0] virus titer at the same level as the infection medium, [−] 
virus titer below the infection medium.
b VACV-mediated cell death was related to uninfected controls (24–72 hpi) and 
measured by MTT cell survival assays. [+] more than 50% of cells were killed by 
LIVP 1.1.1 [−] less than 50% of cells were killed by LIVP 1.1.1.
Treatment condition BV‑2 IMA2.1 BV‑2 IMA2.1
Virus progenya VACV‑mediated 
cell deathb
M2 phenotype
 w/o + 0 + −
 IL-4 + nt + −
M1 phenotype
 IFN-γ − − − −
 IFN-γ + LPS − − − −
 LPS − − − −
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In astrocytic IMA2.1 cells VACV infection was found 
to be independent from the status of polarization. We 
found that VACV LIVP 1.1.1 did not replicate in IMA2.1 
cells. Therefore we concluded that astrocytes restrict the 
oncolytic virus therapy in the mouse brain by not allow-
ing VACV replication to occur.
Immunohistochemical analysis of gliomas treated with 
different classes of oncolytic viruses such as HSV or 
adenovirus have shown intratumoral elimination of over 
80% of viral particles shortly after delivery. The elimina-
tion was shown to be associated with up-regulation and 
infiltration of cells of monocytic lineage both in immu-
nocompetent and in immunodeficient tumor models 
[63, 64], confirming the findings with VACV LIVP 1.1.1 
strain.
OSCs represent an excellent experimental linkage 
between cell cultures and live animal experiments, 
where anatomical, morphological, and cellular function 
of specific brain regions can be maintained and recon-
structed. The main advantage of OSCs is that factors 
such as cell–cell and cell–matrix interactions affect-
ing viral entry or replication are preserved in the intact 
three-dimensional milieu of the brain slice tumors [11]. 
We showed that LIVP 1.1.1 VACV infection resulted in 
no virus replication in GL261-RFP tumor spheres, and 
in contrast, very high replication in U87-MG-RFP tumor 
spheres. The U87-MG cell line is a well-characterized 
cell line that originated from an astrocytic tumor with 
necrosis [65]. It was previously shown that this cell line 
infiltrates brain slice cultures in an in vivo-like manner 
[11, 66, 67].
In addition, cell culture data and the results from 
OSC experiments showed evidence that BV-2 cells were 
infected first by LIVP 1.1.1 when BV-2 cells and GL261 
cells were co-cultured or in a close microenvironment. 
Such infection was dependent on the polarization of the 
cells, e.g. stimulation with IFN-γ prevented BV-2 cells 
from infection with LIVP 1.1.1. IFN-γ mediated anti-
viral effects and mechanisms are reviewed in detail by 
Schroder et al. [68] and Chesler et al. [69].
Since microglial cells respond first to injury or to 
infection and also make up a significant part of the 
tumor mass, we concluded that they were one actual 
target for VACV uptake and infection. We propose 
that possible therapeutic approaches could be directed 
towards the modification of glioma-associated micro-
glia. Successful VACV infection of gliomas could be 
altered by pre-stimulation of microglial cells so that, in 
consequence, tumor cells would be infected in the first 
instance. However, it is important to note that this study 
is based on cell lines that may not reflect exactly the 
behavior of primary cells, which needs to be shown in 
future studies.
As an outlook we assume that biopsies of individual 
cancer patients for ex vivo infection on OSCs could be a 
beneficial test system before starting a particular onco-
lytic virotherapy.
Conclusions
The present study demonstrated that orthotopic GL261 
gliomas in C57BL/6 and FoxN1nu/nu mice were “non-
responder” models for oncolytic virotherapy with VACV 
LIVP 1.1.1. By searching for explanations for this find-
ing we detected that microglia and astrocytes were 
recruited to the tumor sites independent of intratumoral 
virus infection. In cell culture we could clearly show that 
microglia and astrocytes,  dependent on their polariza-
tion into M1/M2 phenotypes,  may preferentially clear 
viral particles by uptake immediately after delivery and 
therefore not allowing efficient virus infection. Based 
on our cell culture findings and OSC studies we assume 
that microglia compete for virus uptake with glioma cells. 
Reasons for reduced virus titers could be due to differ-
ent cell death pathways (apoptosis vs. necrosis) activated 
by VACV infection in microglial BV-2 cells in contrast 
to GL261 tumor cells. Taken together our findings indi-
cate that brain glia cells need to be taken into account for 
future therapy development.
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